Written by: Haylee Knoppe
From live coverage of college football and March Madness, to newly released sitcoms and climactic season finales, television ads remain an integral avenue of advertisement, whether on streaming services or cable television. Recently, there has been an exponential increase in television advertisements for pharmaceutical drugs. From Ozempic to Skyrizi to Jardiance, drugs of all kinds are being clearly and directly advertised to television viewers with catchy jingles and visuals of gleefully healthy actors. This recent uptick in direct-to-consumer advertising (DTCA) of pharmaceutical drugs has several negative implications, both ethical and economic in nature.
Although many viewers have become accustomed to the onslaught of TV drug ads, this is a relatively recent shift in advertising practices. The modern landscape of prescription drug DTCA was established in 1997, when the FDA changed the restrictions of pharmaceutical DTCA by establishing what is known as the “adequate provision” loophole. This provision “allows pharmaceutical advertisements to hide safety information by placing it in another format or location … [such as] a website, toll-free number, or print insert” (U.S. Department of Health and Human Services & Food and Drug Administration, 2025, paras. 6-8). This allowed drug companies to exclude integral information from their advertisements, making television ads more affordable and effective due to the shorter air time necessary to promote a prescription drug. Following this legislative shift, pharmaceutical companies increased investment in direct-to-consumer advertising, from $166 million in 1993 to $4.2 billion in 2005 (IMS Health, 2006, as cited in Donohue, 2006). This established the US as one of only 2.0 countries in the entire world that legally allow direct-to-consumer advertising (Rosenthal, 2024). This begs the question: What concerns discourage every other country in the world from this legal allowance? DTCA of pharmaceutical drugs “can mislead the public about the risks and benefits, encourage medications over lifestyle changes, inappropriately intervene in the physician-patient relationship, and advantage expensive drugs over cheaper generics” (The White House, 2025, para. 1). The promotion of name-brand drugs over more affordable alternatives, overmedication, and general misinformation are just a few negative ramifications of pharmaceutical DTCA with economic implications that promote the nullification of the 1997 “adequate provision” loophole.
It is often perceived that, due to the involvement with the physical livelihood of human beings, healthcare industries should be held to higher ethical standards than, say, a cigarette company or a chain restaurant. However, many aspects of pharmaceutical companies are akin to any business in a market economy, with costs to cover, profits to make, and an incentive to promote sales. This can lead to ethically controversial consequences for consumers and potential patients, especially when considered within the context of the relaxed regulation of the “adequate provision” loophole. Allowing pharmaceutical companies the option to provide external references to supplement an advertisement’s incomplete risk assessment seems to necessitate regulations for these advertisements and references. However, as expressed by Elisabeth Rosenthal (2024) in the Journal of Health Economics and Outcomes Research, the requirements for ads established by the FDA are extremely general, lacking specific parameters and leaving much up to the interpretation of pharmaceutical companies. She also expresses that “ads are not vetted before airing unless the manufacturers voluntarily submit them,” as it is deemed the pharmaceutical company’s responsibility to adhere to compliance (para. 12). She adds that there is seemingly “no FDA police force to decide how the language should be interpreted” (para. 10). This leads to pharmaceutical companies utilizing healthy, happy, attractive individuals, celebrity endorsements, and catchy jingles to promote their drug. Eye-catching graphics boast statistics and graphs that can have overinflated conclusions. This lack of regulation and enforcement allows pharmaceutical advertisements to “overemphasize benefits and minimize risks” (Wang & Kesselheim, 2013, p. 961). This insufficient information prevents consumers from conducting an accurate cost-benefit analysis, causing adverse decision making in risk averse consumers due to their lack of exposure to a full set of information. Thus, the “adequate provision” loophole’s allowance of pharmaceutical DTCA has opened the floodgates to several distinct avenues of misinformation. This can lead to inefficient decision making by consumers.
Pharmaceutical companies are using this lack of regulation to capitalize on name-brand loyalty and trends of overmedication. For example, pharmaceutical direct-to-consumer advertising often encourages consumers to take more expensive, name-brand drugs rather than considering equally effective, generic drugs, which can cause drug prices to rise (Morris et al., 1986 as cited in Donohue, 2006). Generally speaking, the promotion of name-brand drugs increases the market power of dominant pharmaceutical firms. These firms can then start to lean towards monopolistic practices that can have negative impacts on the overall benefit to consumers. In short, informationally favoring premium drug brands causes rising prices, and rising prices have adverse consequences on consumers.
In addition to rising drug prices, promoting name-brand drugs causes the exacerbation of an already overmedicated society (Morris et al., 1986 as cited in Donohue, 2006). This extends to the broader epidemic of overtreatment for inherently human experiences. Pharmaceutical DTCA can misinform consumers, framing completely normal human experiences—like nervousness, shyness, or hair loss—as diseases that require costly, unnecessary drugs (Angell, 2004; Mintzes, 2002, as cited in Donohue, 2006). The promotion of expensive, name-brand drugs, overmedication, and general misinformation of advertisements all have negative ethical and economic consequences to everyday consumers.
However, some individuals promote DTCA of prescription drugs as an idealistic and democratic example of providing more knowledge to everyday consumers. This encourages patients to make a self-informed decision rather than blindly accepting a physician’s advice as the best course of action, encouraging involvement of patients in their own healthcare journey. Generally speaking, knowledge is power; and unbiased, clear information being presented to consumers has noticeable benefits in the outcomes of their decisions.
Unfortunately, this utopian concept is not the reality being faced by everyday individuals. Due to the “adequate provisions” loophole, DTCA by pharmaceutical companies is faced with little regulation to adhere to completely impartial and objective provision of information related to their product. Information provided in prescription drug advertisements can be biased, persuasive, and fragmentary. Among other negative effects, this lack of information can lead to false risk assessments, overmedication, and rising drug prices. These negative effects can promote the revised legislation of the “adequate provision” loophole to establish stricter regulation on pharmaceutical companies’ advertisements.
There are countless ethical concerns stemming from the current under-regulation of pharmaceutical DTCA, from regulatory negligence towards inherently profit-driven pharmaceutical titans, to the disregard of the physical well-being of men, women, and children alike. However, even if all ethical matters are set aside, significant economic concerns remain regarding the implications of the “adequate provision” loophole. Information is the key to efficient decisions, and decision making is the root of economic analysis. Consumers cannot make decisions about their health that maximize their benefit and promote a balanced equilibrium if they are not presented with accurate and thorough information. Thus, general misinformation and misguidance of the public through under-regulated direct-to-consumer advertisements of prescription drugs is not just an ethical matter: It is a cause for extreme economic concern.
References
Donohue, J. (2006). A history of drug advertising: The evolving roles of consumers and consumer protection. Milbank Quarterly, 84(4), 659–699. https://doi.org/10.1111/j.1468-0009.2006.00464.x
Potter, C. (2012). Prescription prices ver 3 [Photograph]. Flickr. https://www.flickr.com/photos/86530412@N02/8266476742
Rosenthal, E. (2024). With TV Drug Ads, What You See Is Not Necessarily What You Get. Journal of Health Economics and Outcomes Research. Jheor.org. https://jheor.org/post/2674-with-tv-drug-ads-what-you-see-is-not-necessarily-%20what-you-ge
The White House. (2025, September 9). Memorandum for the Secretary of Health and Human Services and the Commissioner of Food and Drugs: Addressing misleading direct-to-consumer prescription drug advertisements. https://www.whitehouse.gov/presidential-actions/2025/09/memorandum-for-the-secretary-of-health-and-human-services-the-commissioner-of-food-and-drugs/
U.S. Department of Health and Human Services & Food and Drug Administration. (2025, September 9). Fact sheet: Ensuring patient safety through reform of direct-to-consumer pharmaceutical advertisement policies. https://www.hhs.gov/press-room/hhs-fda-drug-ad-transparency-fact-sheet.html
Wang, B., & Kesselheim, A. S. (2013). The role of direct‑to‑consumer pharmaceutical advertising in patient consumerism. Virtual Mentor, 15(11), 960–965. https://doi.org/10.1001/virtualmentor.2013.15.11.pfor1-1311